Chem-CRISPR/dCas9FCPF: a platform for chemically induced epigenome editing

Area of Science:

• Molecular Biology
• Epigenetics
• Cancer Research

Background:

• Epigenetic alterations drive cancer and chemotherapy resistance.
• Existing epigenetic modulators face challenges with toxicity and specificity.
• CRISPR/dCas9 offers precise epigenetic modulation but has delivery and side-effect concerns.

Purpose of the Study:

• To develop a chemically inducible epigenome editing platform.
• To enhance the specificity of epigenetic inhibitors using CRISPR/dCas9 technology.
• To address the limitations of current epigenetic therapies.

Main Methods:

• Integration of a Phe-Cys-Pro-Phe (FCPF)-peptide tag into dCas9.
• Development of perfluorobiphenyl (PFB) derivatives for chemical targeting.
• Design of chemical inhibitor-PFB conjugates, exemplified by a JQ1-PFB conjugate.
• Application of the Chem-CRISPR/dCas9FCPF system for targeted epigenetic modulation near the c-MYC promoter.

Main Results:

• Established a chemically inducible epigenome editing platform (Chem-CRISPR/dCas9FCPF).
• Demonstrated that c-MYC-sgRNA-guided JQ1-PFB specifically inhibits BRD4 near the c-MYC promoter.
• Showed effective repression of c-MYC-driven transcription networks with improved specificity compared to JQ1 alone.

Conclusions:

• The Chem-CRISPR/dCas9FCPF platform significantly improves target specificity of chemical epigenetic inhibitors.
• This system offers a viable alternative to conventional fusion protein approaches for epigenome editing.
• Provides a precise and potentially less toxic method for epigenetic modulation in cancer therapy.